The Role of Azithromycin in Patients with Cystic Fibrosis

被引：38
作者：
Yousef, Abdullah A. [1 ,2 ,3 ]
Jaffe, Adam [2 ,3 ]
机构：
[1] King Faisal Univ, Dept Paediat, Dammam, Saudi Arabia
[2] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia
[3] Sydney Childrens Hosp, Dept Resp Med, Randwick, NSW 2031, Australia
来源：
PAEDIATRIC RESPIRATORY REVIEWS | 2010年 / 11卷 / 02期
关键词：
macrolides; cystic fibrosis; inflammation; azithromycin; BRONCHIAL EPITHELIAL-CELLS; 14-MEMBERED RING MACROLIDES; LONG-TERM AZITHROMYCIN; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; DIFFUSE PANBRONCHIOLITIS; IN-VITRO; CYTOKINE PRODUCTION; CONTROLLED-TRIAL; ERYTHROMYCIN;
D O I：
10.1016/j.prrv.2009.12.003
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Interest in azithromycin in the management of patients with cystic fibrosis has grown over the last decade. Uniquely this drug has both antibacterial and immune modulating effects which appear to be the reason for its clinical benefit as proven in several well designed clinical studies. In this review we discuss the proposed mechanisms of action of azithromycin and review the evidence for its clinical effectiveness and safety in cystic fibrosis. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：108 / 114
页数：7
相关论文
共 57 条
[1]   ERYTHROMYCIN SHORTENS NEUTROPHIL SURVIVAL BY ACCELERATING APOPTOSIS [J].
AOSHIBA, K ;
NAGAI, A ;
KONNO, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :872-877
[2]   Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin [J].
Baumann, U ;
Fischer, JJ ;
Gudowius, P ;
Lingner, M ;
Herrmann, S ;
Tümmler, B ;
von der Hardt, H .
INFECTION, 2001, 29 (01) :7-11
[3]  
BERGAMINI G, 2008, AM J RESP CELL MOL B
[4]   Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial [J].
Clement, A. ;
Tamalet, A. ;
Leroux, E. ;
Ravilly, S. ;
Fauroux, B. ;
Jais, J-P .
THORAX, 2006, 61 (10) :895-902
[5]   Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects [J].
Culic, O ;
Erakovic, V ;
Cepelak, I ;
Barisic, K ;
Brajsa, K ;
Ferencic, Z ;
Galovic, R ;
Glojnaric, I ;
Manojlovic, Z ;
Munic, V ;
Novak-Mircetic, R ;
Pavicic-Beljak, V ;
Sucic, M ;
Veljaca, M ;
Zanic-Grubisic, T ;
Parnham, MJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (03) :277-289
[6]   Erythromycin suppresses nuclear factor-κB and activator protein-1 activation in human bronchial epithelial cells [J].
Desaki, M ;
Takizawa, H ;
Ohtoshi, T ;
Kasama, T ;
Kobayashi, K ;
Sunazuka, T ;
Omura, S ;
Yamamoto, K ;
Ito, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 267 (01) :124-128
[7]   Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial [J].
Equi, A ;
Balfour-Lynn, IM ;
Bush, A ;
Rosenthal, M .
LANCET, 2002, 360 (9338) :978-984
[8]   The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro [J].
Feldman, C ;
Anderson, R ;
Theron, A ;
Mokgobu, I ;
Cole, PJ ;
Wilson, R .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (05) :1022-1028
[9]   THE CHANGING EPIDEMIOLOGY OF CYSTIC-FIBROSIS [J].
FITZSIMMONS, SC .
JOURNAL OF PEDIATRICS, 1993, 122 (01) :1-9
[10]  
FLORESCU DF, 2009, PULM PHARM THER
123456